Evidence map›Paper›PMID 38243134›Full record

ArticleEuropean radiology2024

Are dilution, slow injection and care bolus technique the causal solution to mitigating arterial-phase artifacts on gadoxetic acid-enhanced MRI? A large-cohort study.

Sarah Poetter-Lang, Raphael Ambros, Alina Messner, Antonia Kristic, Jacqueline C Hodge, Nina Bastati, Wolfgang Schima, Victoria Chernyak, Mustafa R Bashir, Ahmed Ba-Ssalamah

Open access · hybridAbstract read
In one paragraph

Article in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. [Expert consensus on overall standardized management of gadoxetate disodium-enhanced MRI examinations (version 2026)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Sarah Poetter-LangDepartment of Biomedical Imaging and Image-Guided Therapy, Medical University, General Hospital of Vienna (AKH), Waehringer Guertel 18-20, 1090, Vienna, Austria.
Raphael AmbrosDepartment of Diagnostic and Interventional Radiology, Clinic Donaustadt, Vienna Healthcare Group, Vienna, Austria.
Alina MessnerDepartment of Biomedical Imaging and Image-Guided Therapy, Medical University, General Hospital of Vienna (AKH), Waehringer Guertel 18-20, 1090, Vienna, Austria.
Antonia KristicDepartment of Biomedical Imaging and Image-Guided Therapy, Medical University, General Hospital of Vienna (AKH), Waehringer Guertel 18-20, 1090, Vienna, Austria.
Jacqueline C HodgeDepartment of Biomedical Imaging and Image-Guided Therapy, Medical University, General Hospital of Vienna (AKH), Waehringer Guertel 18-20, 1090, Vienna, Austria.
Nina BastatiDepartment of Biomedical Imaging and Image-Guided Therapy, Medical University, General Hospital of Vienna (AKH), Waehringer Guertel 18-20, 1090, Vienna, Austria.
Wolfgang SchimaDepartment of Diagnostic and Interventional Radiology, Goettlicher Heiland Krankenhaus, Barmherzige Schwestern Krankenhaus, and Sankt Josef Krankenhaus, Vienna, Austria.
Victoria ChernyakDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Mustafa R BashirDepartment of Radiology, Duke University Medical Center, Durham, NC, USA.
Ahmed Ba-SsalamahDepartment of Biomedical Imaging and Image-Guided Therapy, Medical University, General Hospital of Vienna (AKH), Waehringer Guertel 18-20, 1090, Vienna, Austria. ahmed.ba-ssalamah@meduniwien.ac.at.ORCID http://orcid.org/0000-0002-3527-404X
Vienna General Hospital · ATBarmherzige Schwestern Krankenhaus Wien · ATDonauspital · ATDuke Medical Center · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectiveArterial-phase artifacts are gadoxetic acid (GA)-enhanced MRI's major drawback, ranging from 5 to 39%. We evaluate the effect of dilution and slow injection of GA using automated fluoroscopic triggering on liver MRI arterial-phase (AP) acquisition timing, artifact frequency, and lesion visibility. METHODS AND MATERIALS: Saline-diluted 1:1 GA was injected at 1 ml/s into 1413 patients for 3 T liver MRI. Initially, one senior abdominal radiologist, i.e., principal investigator (PI), assessed all MR exams and compared them to previous and follow-up images, as well as the radiology report on record, determining the standard of reference for lesion detection and characterization. Then, three other readers independently evaluated the AP images for artifact type (truncation (TA), transient severe motion (TSM) or mixed), artifact severity (on a 5-point scale), acquisition timing (on a 4-point scale) and visibility (on a 5-point scale) of hypervascular lesions ≥ 5 mm, selected by the PI. Artifact score ≥ 4 and artifact score ≤ 3 were considered significant and non-significant artifacts, respectively.

resultsOf the 1413 exams, diagnostic-quality arterial-phase images included 1100 (77.8%) without artifacts, 220 (15.6%) with minimal, and 77 (5.4%) with moderate artifacts. Only 16 exams (1.1%) had significant artifacts, 13 (0.9%) with severe artifacts (score 4), and three (0.2%) non-diagnostic artifacts (score 5). AP acquisition timing was optimal in 1369 (96.8%) exams. Of the 449 AP hypervascular lesions, 432 (96.2%) were detected.

conclusionCombined dilution and slow injection of GA with MR results in well-timed arterial-phase images in 96.8% and a reduction of exams with significant artifacts to 1.1%. CLINICAL RELEVANCE STATEMENT: Hypervascular lesions, in particular HCC detection, hinge on arterial-phase hyperenhancement, making well-timed, artifact-free arterial-phase images a prerequisite for accurate diagnosis. Saline dilution 1:1, slow injection (1 ml/s), and automated bolus triggering reduce artifacts and optimize acquisition timing. KEY POINTS: • There was substantial agreement among the three readers regarding the presence and type of arterial-phase (AP) artifacts, acquisition timing, and lesion visibility. • Impaired AP hypervascular lesion visibility occurred in 17 (3.8%) cases; in eight lesions due to mistiming and in nine lesions due to significant artifacts. • When AP timing was suboptimal, it was too late in 40 exams (3%) and too early in 4 exams (0.2%) of exams.

Indexed as

ArtifactsContrast MediaGadolinium DTPAMagnetic Resonance ImagingAdultAgedAged, 80 and overCohort StudiesFemaleHumansImage EnhancementLiverLiver NeoplasmsMaleMiddle AgedYoung AdultContrast MediaGadolinium DTPAgadolinium ethoxybenzyl DTPAArtifactsContrast mediaLiverMagnetic resonance imaging

Identifiers

PMID38243134
PMCPMC11254987
OpenAlexW4391042774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.